Monoamine transporter pharmacology and mutant mice

Trends in Pharmacological Sciences

Volumn 23, Issue 8, 2002, Pages 367-373

  Gainetdinov, Raul R ^a   Sotnikova, Tatyana D ^a   Caron, Marc G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 5 HYDROXYTRYPTOPHAN; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMPHETAMINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOZAPINE; COCAINE; DESIPRAMINE; DIZOCILPINE; DOPAMINE TRANSPORTER; FLUOXETINE; HALOPERIDOL; METHAMPHETAMINE; METHYLPHENIDATE; METIROSINE; MODAFINIL; MORPHINE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; NEUROTRANSMITTER; NISOXETINE; NOMIFENSINE; NORADRENALIN; PARGYLINE; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; RACLOPRIDE; REBOXETINE; TOLCAPONE; UNINDEXED DRUG; VANOXERINE;

AMINE TRANSPORT; CELL MEMBRANE; DRUG MECHANISM; DRUG SELECTIVITY; GENE DELETION; GENETIC CODE; IN VIVO STUDY; MOUSE; MUTANT; NEUROTRANSMISSION; NONHUMAN; PRESYNAPTIC NERVE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BIOGENIC MONOAMINES; CARRIER PROTEINS; CELL MEMBRANE; MICE; MICE, KNOCKOUT; PSYCHOTROPIC DRUGS;

EID: 0036696274     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(02)02044-8     Document Type: Review

References (60)

1. Carlsson A., et al. Interaction between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 41:2001;237-260.
2. Greengard P. The neurobiology of slow synaptic transmission. Science. 294:2001;1024-1030.
3. Amara S.G., Kuhar M.J. Neurotransmitter transporters: recent progress. Annu. Rev. Neurosci. 16:1993;73-93.
4. Giros B., Caron M.G. Molecular characterization of the dopamine transporter. Trends Pharmacol. Sci. 14:1993;43-49.
5. Uhl G.R., Kitayama S. A cloned dopamine transporter. Potential insights into Parkinson's disease pathogenesis. Adv. Neurol. 60:1993;321-324.
6. Blakely R.D., et al. Molecular physiology of norepinephrine and serotonin transporters. J. Exp. Biol. 196:1994;263-281.
7. Miller G.W., et al. Dopamine transporters and neuronal injury. Trends Pharmacol. Sci. 20:1999;424-429.
8. Cases O., et al. Plasma membrane transporters of serotonin, dopamine, and norepinephrine mediate serotonin accumulation in atypical locations in the developing brain of monoamine oxidase A knock-outs. J. Neurosci. 18:1998;6914-6927.
9. Pan Y., et al. Plasticity in serotonin uptake in primary neuronal cultures of serotonin transporter knockout mice. Dev. Brain Res. 126:2001;125-129.
10. Moron J.A., et al. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J. Neurosci. 22:2002;389-395.
11. Giros B., et al. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 379:1996;606-612.
12. Bengel D., et al. Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ('Ecstasy') in serotonin transporter-deficient mice. Mol. Pharmacol. 53:1998;649-655.
13. Xu F., et al. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat. Neurosci. 3:2000;465-471.
14. Sora I., et al. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc. Natl. Acad. Sci. U. S. A. 95:1998;7699-7704.
15. Jones S.R., et al. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc. Natl. Acad. Sci. U. S. A. 95:1998;4029-4034.
16. Gainetdinov R.R., et al. Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Res. Rev. 26:1998;148-153.
17. Benoit-Marand M., et al. Release and elimination of dopamine in vivo in mice lacking the dopamine transporter: functional consequences. Eur. J. Neurosci. 12:2000;2985-2992.
18. Jones S.R., et al. Loss of autoreceptor functions in mice lacking the dopamine transporter. Nat. Neurosci. 2:1999;649-655.
19. Gainetdinov R.R., et al. Functional hyperdopaminergia in dopamine transporter knock-out mice. Biol. Psychiatry. 46:1999;303-311.
20. Fauchey V., et al. Differential regulation of the dopamine D1, D2 and D3 receptor gene expression and changes in the phenotype of the striatal neurons in mice lacking the dopamine transporter. Eur. J. Neurosci. 12:2000;19-26.
21. Gainetdinov R.R., et al. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science. 283:1999;397-401.
22. Spielewoy C., et al. Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice. Behav. Pharmacol. 11:2000;279-290.
23. Bosse R., et al. Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter. Neuron. 19:1997;127-138.
24. Ralph R.J., et al. Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. J. Neurosci. 21:2001;305-313.
25. Wisor J.P., et al. Dopaminergic role in stimulant-induced wakefulness. J. Neurosci. 21:2001;1787-1794.
26. Bliziotes M., et al. Bone histomorphometric and biomechanical abnormalities in mice homozygous for deletion of the dopamine transporter gene. Bone. 26:2000;15-19.
27. Walker J.K., et al. Mice lacking the dopamine transporter display altered regulation of distal colonic motility. Am. J. Physiol. Gastrointest. Liver Physiol. 279:2000;G311-318.
28. Seiden L.S., et al. Amphetamine: effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. Toxicol. 33:1993;639-677.
29. Sulzer D., et al. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15:1995;4102-4108.
30. Jones S.R., et al. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J. Neurosci. 18:1998;1979-1986.
31. Seiden L.S., Sabol K.E. Neurotoxicity of methamphetamine-related drugs and cocaine. Chang L.W., Dyer R.S., Handbook of Neurotoxicology. 1995;825-843 Marcell Dekker.
32. Fumagalli F., et al. Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J. Neurosci. 18:1998;4861-4869.
33. Gainetdinov R.R., et al. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 69:1997;1322-1325.
34. Bezard E., et al. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp. Neurol. 155:1999;268-273.
35. Rocha B.A., et al. Cocaine self-administration in dopamine transporter knockout mice. Nat. Neurosci. 1:1998;132-137.
36. Wise R.A. Neurobiology of addiction. Curr. Opin. Neurobiol. 6:1996;243-251.
37. Carboni E., et al. Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene. J. Neurosci. 21:2001;1-4.
38. Reith M.E., et al. Extracellular dopamine, norepinephrine, and serotonin in the ventral tegmental area and nucleus accumbens of freely moving rats during intracerebral dialysis following systemic administration of cocaine and other uptake blockers. Psychopharmacology. 134:1997;309-317.
39. Budygin E.A., et al. Lack of cocaine effect on dopamine clearance in the core and shell of the nucleus accumbens of dopamine transporter knock-out mice. J. Neurosci. 22:2002;RC222.
40. Sora I., et al. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc. Natl. Acad. Sci. U. S. A. 98:2001;5300-5305.
41. Spielewoy C., et al. Hypolocomotor effects of acute and daily d-amphetamine in mice lacking the dopamine transporter. Psychopharmacology. 159:2001;2-9.
42. Zhuang X., et al. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc. Natl. Acad. Sci. U. S. A. 98:2001;1982-1987.
43. Hollister A.S., et al. An inhibitory role for brain serotonin-containing systems in the locomotor effects of d-amphetamine. J. Pharmacol. Exp. Ther. 198:1976;12-22.
44. Barkley R.A., Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 1990;Guiford Press.
45. Gainetdinov R.R., Caron M.G. An animal model of attention deficit hyperactivity disorder. Mol. Med. Today. 6:2000;43-44.
46. Aghajanian G.K., Marek G.J. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res. Rev. 31:2000;302-312.
47. Gainetdinov R.R., et al. Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proc. Natl. Acad. Sci. U. S. A. 98:2001;11047-11054.
48. th Annual ACNP Meeting, Waikoloa, Hawaii, p. 271
49. Spielewoy C., et al. Increased rewarding properties of morphine in dopamine-transporter knockout mice. Eur. J. Neurosci. 12:2000;1827-1837.
50. Rattray M. Ecstasy: towards an understanding of the biochemical basis of the actions of MDMA. Essays Biochem. 26:1991;77-87.
51. Murphy D.L., et al. Consequences of engineered and spontaneous genetic alterations of the 5-HT transporter in mice, men and women. Behav. Pharmacol. 10:(Suppl. 1):1999;S65.
52. 1B receptors in knock-out mice lacking the 5-HT transporter. Eur. J. Neurosci. 12:2000;2299-2310.
53. Gobbi G., et al. Modifications of the serotonergic system in mice lacking serotonin transporters: an in vivo electrophysiological study. J. Pharmacol. Exp. Ther. 296:2001;987-995.
54. 1A binding sites in 5-HT transporter knockout mice. J. Pharmacol. Exp. Ther. 291:1999;999-1007.
55. 2A receptors in mice lacking the serotonin transporter. Neurosci. Lett. 262:1999;113-116.
56. Uhl G.R., et al. Copcaine, reward, movement and monoamine transporters. Mol. Psychiatry. 7:2002;21-26.
57. Bohn L.M., et al. Potentiated opioid analgesia in norepinephrine transporter knock-out mice. J. Neurosci. 20:2000;9040-9045.
58. Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int. Clin. Psychopharmacol. 12:(Suppl. 3):1997;S7-S14.
59. Avni J., et al. Norepinephrine content of various rat organs after chronic administration of desmethylimipramine. Arch. Int. Pharmacodyn. Ther. 218:1975;106-109.
60. Wilson J.M., et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 2:1996;699-703.